Literature DB >> 12807436

Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein.

Merja Lakso1, Suvi Vartiainen, Anu-Maarit Moilanen, Jouni Sirviö, James H Thomas, Richard Nass, Randy D Blakely, Garry Wong.   

Abstract

Overexpression of human alpha-synuclein in model systems, including cultured neurons, drosophila and mice, leads to biochemical and pathological changes that mimic synucleopathies including Parkinson's disease. We have overexpressed both wild-type (WT) and mutant alanine53-->threonine (A53T) human alpha-synuclein by transgenic injection into Caenorhabditis elegans. Motor deficits were observed when either WT or A53T alpha-synuclein was overexpressed with a pan-neuronal or motor neuron promoter. Neuronal and dendritic loss were accelerated in all three sets of C. elegans dopaminergic neurons when human alpha-synuclein was overexpressed under the control of a dopaminergic neuron or pan-neuronal promoter, but not with a motor neuron promoter. There were no significant differences in neuronal loss between overexpressed WT and A53T forms or between worms of different ages (4 days, 10 days or 2 weeks). These results demonstrate neuronal and behavioral perturbations elicited by human alpha-synuclein in C. elegans that are dependent upon expression in specific neuron subtypes. This transgenic model in C. elegans, an invertebrate organism with excellent experimental resources for further genetic manipulation, may help facilitate dissection of pathophysiologic mechanisms of various synucleopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807436     DOI: 10.1046/j.1471-4159.2003.01809.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  134 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

Review 2.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

3.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

4.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 5.  Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.

Authors:  Fernando Calahorro; Manuel Ruiz-Rubio
Journal:  Invert Neurosci       Date:  2011-11-08

6.  The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.

Authors:  Erin K Butler; Aaron Voigt; A Kathrin Lutz; Jane P Toegel; Ellen Gerhardt; Peter Karsten; Björn Falkenburger; Andrea Reinartz; Konstanze F Winklhofer; Jörg B Schulz
Journal:  PLoS Genet       Date:  2012-02-02       Impact factor: 5.917

Review 7.  Dopamine signaling architecture in Caenorhabditis elegans.

Authors:  Paul W McDonald; Tammy Jessen; Julie R Field; Randy D Blakely
Journal:  Cell Mol Neurobiol       Date:  2006-05-25       Impact factor: 5.046

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 9.  Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans.

Authors:  Gary A Silverman; Cliff J Luke; Sangeeta R Bhatia; Olivia S Long; Anne C Vetica; David H Perlmutter; Stephen C Pak
Journal:  Pediatr Res       Date:  2009-01       Impact factor: 3.756

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.